Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients
SHAVE2
A Multicenter Randomized Controlled Trial of Routine Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients
1 other identifier
interventional
400
1 country
9
Brief Summary
Breast cancer is the most common malignancy affecting women in the US. Surgical management is the mainstay of therapy, and in general consists of resection of the primary tumor with either a partial mastectomy (aka "lumpectomy") or a total mastectomy. The investigators hypothesize that routine shave margins during partial mastectomy will significantly reduce positive margin rate. A positive margin means that cancerous cells were detected at the edge of the excised area. This generally mandates a return to the operating room for re-excision.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable breast-cancer
Started Jul 2016
Longer than P75 for not_applicable breast-cancer
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 9, 2016
CompletedFirst Posted
Study publicly available on registry
May 13, 2016
CompletedStudy Start
First participant enrolled
July 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2024
CompletedJanuary 31, 2025
January 1, 2025
1.9 years
May 9, 2016
January 30, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Positive margin rate
The effect is positive margin rate post-surgery as measured by local pathological reports. Positive margins were defined as tumor touching the edge of the specimen that was removed in patients with invasive cancer and tumor that was within 2 mm of the edge of the specimen removed in those with ductal carcinoma in situ.
immediately after surgery
Secondary Outcomes (6)
local recurrence rates
up to 5 years
patient perceived cosmesis
1 year post-op
patient perceived cosmesis
5 years post-op
volume of tissue resected
immediately after tissue resection
Quality of Life assessment
1 year post-op about the last seven days
- +1 more secondary outcomes
Study Arms (2)
Shave Margin
EXPERIMENTALAfter partial mastectomy, patients will be subject to intraoperative randomization to the shave margin group where additional tissue will be resected.
No Shave Margin
ACTIVE COMPARATORAfter partial mastectomy, patients will be subject to intraoperative randomization to the no shave margin group, where after initial surgery, no further tissue will be removed.
Interventions
For the shave group, additional superior, inferior, medial and lateral margins will be removed, oriented, and sent for pathologic evaluation at the local site. Resection of additional anterior and posterior margins will be left to surgeon discretion, as this will depend on if skin or fascia was taken. All surgeons participating in the study will be educated on the expectation of what is considered a "shave margin". A shave margin is defined as an additional segment of breast tissue taken from each of the superior, inferior, medial, and lateral aspects of the cavity, such that the entire circumference of the cavity is re-excised following this procedure. Orientation of each shaved margin will be done to mark the true margin.
Surgeons will be instructed to close after partial mastectomy with no further excision.
Eligibility Criteria
You may qualify if:
- Breast cancer, stage 0-3, deemed a surgically appropriate candidate for partial mastectomy with planned procedure for the same
- Women ≥ 18 years of age
- Ability to understand and the willingness to sign a written informed consent document.
- Exlusion Criteria
- Total mastectomy
- Known metastatic disease
- Bilateral synchronous breast cancer
- Multicentric cancers requiring double lumpectomy
- Previous history of breast cancer (even in the other breast)
- Patients receiving Intraoperative radiation therapy (IORT)
- Patients who had excisional biopsy for diagnosis of their cancer (I.e., instead of a core biopsy)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Yale Universitylead
Study Sites (9)
Loma Linda University Cancer Center
Loma Linda, California, 92354, United States
Watson Clinic Cancer and Research Center
Lakeland, Florida, 33805, United States
William Beaumont Hospital
Troy, Michigan, 48085, United States
UNC Chapel Hill
Chapel Hill, North Carolina, 27599-7213, United States
Wake Forest School of Medicine
Winston-Salem, North Carolina, 27157, United States
Cleveland Clinic Akron General
Akron, Ohio, 44307, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Women & Infants Hospital
Providence, Rhode Island, 02905, United States
Doctors Hospital at Renaissance
Edinburg, Texas, 78539, United States
Related Publications (1)
Chagpar AB, Killelea BK, Tsangaris TN, Butler M, Stavris K, Li F, Yao X, Bossuyt V, Harigopal M, Lannin DR, Pusztai L, Horowitz NR. A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. N Engl J Med. 2015 Aug 6;373(6):503-10. doi: 10.1056/NEJMoa1504473. Epub 2015 May 30.
PMID: 26028131BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Anees Chagpar, MD
Yale University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 9, 2016
First Posted
May 13, 2016
Study Start
July 1, 2016
Primary Completion
June 1, 2018
Study Completion
November 1, 2024
Last Updated
January 31, 2025
Record last verified: 2025-01
Data Sharing
- IPD Sharing
- Will not share